Jazz Pharmaceuticals plc
Company Stats
- Market Cap
- $15.0B
- as of Sep 30, 2026
- Enterprise Value
- $19.0B
- Shares Outstanding
- 64.9M
- Free Float
- 66.1%
Income Statement
- Revenue
- $4.3B
- Operating Income
- -$430.2M
- Net Income
- -$356.1M
- EBITDA
- -$388.6M
- Revenue Growth, 3Y
- 5.3%
- FCF Margin, 3Y Avg
- 30.5%
- FCF Margin, Worst Year
- 27.9%
Cash Flow
- Free Cash Flow
- $1.3B
- FCF Yield
- 8.6%
- Owner FCF Yield
- 6.7%
Balance Sheet
- Cash & Equivalents
- $1.4B
- Total Debt
- $5.4B
- Net Debt
- $4.0B
Returns & Capital
- Share Repurchases
- $125.0M
- Buyback Yield, 3Y Avg
- 1.6%
- SBC, 3Y Avg
- $255.3M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $4.3B | $1.3B | 30.4% |
| FY2024 | $4.1B | $1.4B | 33.4% |
| FY2023 | $3.8B | $1.1B | 27.9% |
| FY2022 | $3.7B | $1.2B | 34.0% |
| FY2021 | $3.1B | $750.9M | 24.3% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 28, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Jazz Pharmaceuticals to Buy Actio Biosciences in $820 Million Mixed Deal